Literature DB >> 27422057

Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells.

Meng Li1, Huashan Zhao1, Gene E Ananiev2, Michael T Musser1, Kathryn H Ness1, Dianne L Maglaque1, Krishanu Saha3,4, Anita Bhattacharyya1, Xinyu Zhao1,5.   

Abstract

Human patient-derived induced pluripotent stem cells (hiPSCs) provide unique opportunities for disease modeling and drug development. However, adapting hiPSCs or their differentiated progenies to high throughput assays for phenotyping or drug screening has been challenging. Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and a major genetic cause of autism. FXS is caused by mutational trinucleotide expansion in the FMR1 gene leading to hypermethylation and gene silencing. One potential therapeutic strategy is to reactivate the silenced FMR1 gene, which has been attempted using both candidate chemicals and cell-based screening. However, molecules that effectively reactivate the silenced FMR1 gene are yet to be identified; therefore, a high throughput unbiased screen is needed. Here we demonstrate the creation of a robust FMR1-Nluc reporter hiPSC line by knocking in a Nano luciferase (Nluc) gene into the endogenous human FMR1 gene using the CRISPR/Cas9 genome editing method. We confirmed that luciferase activities faithfully report FMR1 gene expression levels and showed that neural progenitor cells derived from this line could be optimized for high throughput screening. The FMR1-Nluc reporter line is a good resource for drug screening as well as for testing potential genetic reactivation strategies. In addition, our data provide valuable information for the generation of knockin human iPSC reporter lines for disease modeling, drug screening, and mechanistic studies. Stem Cells 2017;35:158-169.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Drug discovery; FMR1; FMRP; Fragile X syndrome; High throughput; Induced pluripotent stem cells; Luciferase

Mesh:

Substances:

Year:  2016        PMID: 27422057      PMCID: PMC5195860          DOI: 10.1002/stem.2463

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  46 in total

1.  iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth.

Authors:  Matthew E Doers; Michael T Musser; Robert Nichol; Erich R Berndt; Mei Baker; Timothy M Gomez; Su-Chun Zhang; Leonard Abbeduto; Anita Bhattacharyya
Journal:  Stem Cells Dev       Date:  2014-04-30       Impact factor: 3.272

2.  Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome.

Authors:  Weixiang Guo; Adeline C Murthy; Li Zhang; Eric B Johnson; Eric G Schaller; Andrea M Allan; Xinyu Zhao
Journal:  Hum Mol Genet       Date:  2011-11-02       Impact factor: 6.150

3.  Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes.

Authors:  Sebastiano A Musumeci; Giuseppe Calabrese; Carmela M Bonaccorso; Simona D'Antoni; Judith R Brouwer; Cathy E Bakker; Maurizio Elia; Raffaele Ferri; David L Nelson; Ben A Oostra; Maria Vincenza Catania
Journal:  Exp Neurol       Date:  2006-09-27       Impact factor: 5.330

4.  Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation.

Authors:  J R Brouwer; E J Mientjes; C E Bakker; I M Nieuwenhuizen; L A Severijnen; H C Van der Linde; D L Nelson; B A Oostra; R Willemsen
Journal:  Exp Cell Res       Date:  2006-10-13       Impact factor: 3.905

5.  Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.

Authors:  Walter E Kaufmann; Ranon Cortell; Alice S M Kau; Irena Bukelis; Elaine Tierney; Robert M Gray; Christiane Cox; George T Capone; Pia Stanard
Journal:  Am J Med Genet A       Date:  2004-09-01       Impact factor: 2.802

6.  Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.

Authors:  Roberta Pietrobono; Maria Grazia Pomponi; Elisabetta Tabolacci; Ben Oostra; Pietro Chiurazzi; Giovanni Neri
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

Review 7.  Phenotypic variation and FMRP levels in fragile X.

Authors:  Danuta Z Loesch; Richard M Huggins; Randi J Hagerman
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004

8.  Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.

Authors:  Daman Kumari; Aditi Bhattacharya; Jeffrey Nadel; Kristen Moulton; Nicole M Zeak; Anne Glicksman; Carl Dobkin; David J Brick; Philip H Schwartz; Carolyn B Smith; Eric Klann; Karen Usdin
Journal:  Hum Mutat       Date:  2014-12       Impact factor: 4.878

9.  Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells.

Authors:  Achia Urbach; Ori Bar-Nur; George Q Daley; Nissim Benvenisty
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

Review 10.  Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.

Authors:  Eric E Schadt; Sean Buchanan; Kristen J Brennand; Kalpana M Merchant
Journal:  Front Pharmacol       Date:  2014-12-02       Impact factor: 5.810

View more
  18 in total

Review 1.  Induced pluripotent stem cell technology: a decade of progress.

Authors:  Yanhong Shi; Haruhisa Inoue; Joseph C Wu; Shinya Yamanaka
Journal:  Nat Rev Drug Discov       Date:  2016-12-16       Impact factor: 84.694

Review 2.  Human Models Are Needed for Studying Human Neurodevelopmental Disorders.

Authors:  Xinyu Zhao; Anita Bhattacharyya
Journal:  Am J Hum Genet       Date:  2018-12-06       Impact factor: 11.025

Review 3.  Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.

Authors:  Sudhanshu P Raikwar; Nidhi S Kikkeri; Ragha Sakuru; Daniyal Saeed; Haris Zahoor; Keerthivaas Premkumar; Shireen Mentor; Ramasamy Thangavel; Iuliia Dubova; Mohammad Ejaz Ahmed; Govindhasamy P Selvakumar; Duraisamy Kempuraj; Smita Zaheer; Shankar S Iyer; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-23       Impact factor: 4.147

Review 4.  Human induced pluripotent stem cells for modelling neurodevelopmental disorders.

Authors:  Karthikeyan Ardhanareeswaran; Jessica Mariani; Gianfilippo Coppola; Alexej Abyzov; Flora M Vaccarino
Journal:  Nat Rev Neurol       Date:  2017-04-18       Impact factor: 42.937

Review 5.  Stem Cells, Genome Editing, and the Path to Translational Medicine.

Authors:  Frank Soldner; Rudolf Jaenisch
Journal:  Cell       Date:  2018-10-18       Impact factor: 41.582

Review 6.  Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies.

Authors:  K R Sabitha; Ashok K Shetty; Dinesh Upadhya
Journal:  Neurosci Biobehav Rev       Date:  2020-12-25       Impact factor: 8.989

Review 7.  Therapeutic gene editing: delivery and regulatory perspectives.

Authors:  Gayong Shim; Dongyoon Kim; Gyu Thae Park; Hyerim Jin; Soo-Kyung Suh; Yu-Kyoung Oh
Journal:  Acta Pharmacol Sin       Date:  2017-04-10       Impact factor: 6.150

8.  Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease.

Authors:  Yi-Ying Wu; Feng-Lan Chiu; Chan-Shien Yeh; Hung-Chih Kuo
Journal:  Open Biol       Date:  2019-01-31       Impact factor: 6.411

Review 9.  Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells.

Authors:  Hagar Mor-Shaked; Rachel Eiges
Journal:  Genes (Basel)       Date:  2016-09-28       Impact factor: 4.096

10.  Expression-based drug screening of neural progenitor cells from individuals with schizophrenia.

Authors:  Benjamin Readhead; Brigham J Hartley; Brian J Eastwood; David A Collier; David Evans; Richard Farias; Ching He; Gabriel Hoffman; Pamela Sklar; Joel T Dudley; Eric E Schadt; Radoslav Savić; Kristen J Brennand
Journal:  Nat Commun       Date:  2018-10-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.